We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves First Biosimilar to Blockbuster Lucentis for the Treatment of Wet Macular Degeneration and Other Eye Diseases
FDA Approves First Biosimilar to Blockbuster Lucentis for the Treatment of Wet Macular Degeneration and Other Eye Diseases
The FDA has approved Byooviz (ranibizumab-nuna), the first biosimilar to Roche’s blockbuster Lucentis (ranibizumab) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for older Americans.